MedTrace Logo

Study to Compare MultiHance With Gadovist in Magnetic Resonance Imaging (MRI) of the Brain

NCT00907530 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 121

Last updated 2012-01-05

No results posted yet for this study

Summary

This study is being conducted as a phase IV, double-blind, multi-center, randomized, crossover trial aimed at a within-subject comparison of MULTIHANCE and GADOVIST at a dose of 0.1 mmol/kg, in terms of qualitative and quantitative assessment of unenhanced MRI (UE MRI) and contrast-enhanced MRI (CE MRI) for the visualization of brain disease.

Conditions

  • Brain Lesions

Interventions

DRUG

MULTIHANCE:

MULTIHANCE ® 0.5 M,0.1 mmol/kg

DRUG

GADOVIST

GADOVIST ® 1.0 M,0.1 mmol/kg

Sponsors & Collaborators

  • Bracco Diagnostics, Inc

    lead INDUSTRY

Principal Investigators

  • Gianpaolo Pirovano, MD · Bracco Diagnostics

Study Design

Allocation
RANDOMIZED
Purpose
DIAGNOSTIC
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2011-03-31
Completion
2011-07-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00907530 on ClinicalTrials.gov